Lifecore Biomedical (LFCR) closed at $6.38 on October 16, 2026, down 0.9% from the previous close, on volume of 1,421,378 shares (30-day average 504,689).
Data as of October 16, 2026.
16-Oct-2026
Lifecore Biomedical to Participate at Upcoming Industry Conferences
Globe Newswire (Wed, 7-Oct 4:05 PM ET)
Are RXO, PTC, LFCR, WAFD Obtaining Fair Deals for their Shareholders?
PRNewswire (Mon, 5-Oct 10:40 PM ET)
Globe Newswire (Sun, 4-Oct 11:58 AM ET)
EQUITY ALERT - The M&A Class Action Firm Launches Inquiry -- FWAC, MGLD, LFCR, and MG
PRNewswire (Sat, 3-Oct 3:00 PM ET)
Globe Newswire (Wed, 30-Sep 9:17 PM ET)
Business Wire (Wed, 30-Sep 7:05 PM ET)
Globe Newswire (Wed, 30-Sep 4:11 PM ET)
PRNewswire (Tue, 29-Sep 3:02 PM ET)
Are LFCR, ITGR, FHB, INDV Obtaining Fair Deals for their Shareholders?
PRNewswire (Tue, 29-Sep 1:53 PM ET)
Business Wire (Tue, 29-Sep 8:06 AM ET)
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.
Lifecore Biomedical trades on the NASDAQ stock market under the symbol LFCR.
As of October 16, 2026, LFCR stock price declined to $6.38 with 1,421,378 million shares trading.
LFCR has a beta of 2.39, meaning it tends to be more sensitive to market movements. LFCR has a correlation of 0.12 to the broad based SPY ETF.
LFCR has a market cap of $241.84 million. This is considered a Small Cap stock.
Last quarter Lifecore Biomedical reported $34 million in Revenue and -$.19 earnings per share. This beat revenue expectation by $2 million and exceeded earnings estimates by $.02.
In the last 3 years, LFCR traded as high as $8.98 and as low as $3.63.
The top ETF exchange traded funds that LFCR belongs to (by Net Assets): VTI, IWM, VXF, IWN, VTWO.
LFCR has underperformed the market in the last year with a price return of -2.3% while the SPY ETF gained +16.7%. However, in the short term, LFCR had mixed performance relative to the market. It has outperformed in the last 3 months, returning +28.9% vs +1.9% return in SPY. But in the last 2 weeks, LFCR shares have been beat by the market, returning -2.4% compared to an SPY return of -0.8%.
LFCR support price is $6.27 and resistance is $6.61 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LFCR shares will trade within this expected range on the day.